Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Sporn

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Scientific Reports|February 23, 2012
Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitisTej K Pareek, Abdelmadjid Belkadi, Sashi Kesavapany, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2005
Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stressAlbena T Dinkova-Kostova, Karen T Liby, Katherine K Stephenson, et al.
Blood|September 28, 2002
The triterpenoid CDDO induces apoptosis in refractory CLL B cellsIrene M Pedersen, Shinichi Kitada, Aaron Schimmer, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 15, 2019
Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer PreventionDi Zhang, Ana S Leal, Sarah Carapellucci, et al.
Journal of Neurochemistry|February 17, 2015
Neuroprotective role of Nrf2 for retinal ganglion cells in ischemia-reperfusionZhenhua Xu, Hongkwan Cho, Matthew J Hartsock, et al.
Cancer Research|March 22, 2003
Synthetic triterpenoids enhance transforming growth factor beta/Smad signalingNanjoo Suh, Anita B Roberts, Stephanie Birkey Reffey, et al.
Molecular Cancer Therapeutics|May 17, 2008
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesisKaren Liby, Candice C Black, Darlene B Royce, et al.
Cancer Research|June 3, 2005
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signalingKaren Liby, Thomas Hock, Mark M Yore, et al.
Blood|April 9, 2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistanceDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancerSrinivas Nagaraj, Je-In Youn, Hannah Weber, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Scientific Reports|February 23, 2012
Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitisTej K Pareek, Abdelmadjid Belkadi, Sashi Kesavapany, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2005
Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stressAlbena T Dinkova-Kostova, Karen T Liby, Katherine K Stephenson, et al.
Blood|September 28, 2002
The triterpenoid CDDO induces apoptosis in refractory CLL B cellsIrene M Pedersen, Shinichi Kitada, Aaron Schimmer, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 15, 2019
Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer PreventionDi Zhang, Ana S Leal, Sarah Carapellucci, et al.
Journal of Neurochemistry|February 17, 2015
Neuroprotective role of Nrf2 for retinal ganglion cells in ischemia-reperfusionZhenhua Xu, Hongkwan Cho, Matthew J Hartsock, et al.
Cancer Research|March 22, 2003
Synthetic triterpenoids enhance transforming growth factor beta/Smad signalingNanjoo Suh, Anita B Roberts, Stephanie Birkey Reffey, et al.
Molecular Cancer Therapeutics|May 17, 2008
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesisKaren Liby, Candice C Black, Darlene B Royce, et al.
Cancer Research|June 3, 2005
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signalingKaren Liby, Thomas Hock, Mark M Yore, et al.
Blood|April 9, 2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistanceDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancerSrinivas Nagaraj, Je-In Youn, Hannah Weber, et al.
Pageof 12